I would like to know how other people define, identify and handle
PROGRAM INCOME obtained during the grant period.  For example, a faculty member
develops a new cell line or an antiserum as a part of research sponsored by an
NIH grant.  Which, if any, of the following represent program income:
 1) proceeds of the sale of the cell line or antisera
 2) royalty income from licensing the cell line or antisera
 Does it matter whether or not the cell line is patented?
 On another bulletin board (techno-l) there has been a little bit of
discussion of late and the consenus seems to be that sale of
biological materials developed from NIH funding is DEFINITELY NOT program
income.  From the little I know about program income, this does not seem
logical.  Can anyone shed some light on what I am missing?
 On the federal FSR there are lines for a) Disbursed Program Income,
b) undisbursed program income and c) total program income realized.  To what
does Disbursed Program Income refer, i.e. disbursed where, to whom?  How are
these items interpreted?

Doug Wilkerson, Ph.D.           VOICE:  (419) 381-4252
Assoc. V.P. for Research        FAX:    (419) 381-4262
Professor of Pharmacology       e-mail: xxxxxx@MAGNUM.MCO.EDU
Medical College of Ohio
3000 Arlington Ave.
Toledo, OH 43614